Quoin Pharmaceuticals to Announce Third Quarter 2024 Financial Results on Thursday, November 7, 2024
Quoin Pharmaceuticals (NASDAQ: QNRX), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced it will release its third quarter 2024 financial results before market opens on Thursday, November 7, 2024. The announcement will include an operational update on company achievements during the quarter and financial highlights.
Quoin Pharmaceuticals (NASDAQ: QNRX), una compagnia farmaceutica specializzata in fase clinica focalizzata su malattie rare e orfane, ha annunciato che rilascerà i suoi risultati finanziari del terzo trimestre 2024 prima dell'apertura del mercato giovedì 7 novembre 2024. L'annuncio includerà un aggiornamento operativo sui traguardi raggiunti dall'azienda durante il trimestre e i principali risultati finanziari.
Quoin Pharmaceuticals (NASDAQ: QNRX), una empresa farmacéutica especializada en etapa clínica centrada en enfermedades raras y huérfanas, anunció que publicará sus resultados financieros del tercer trimestre de 2024 antes de la apertura del mercado el jueves 7 de noviembre de 2024. El anuncio incluirá una actualización operativa sobre los logros de la empresa durante el trimestre y los aspectos destacados financieros.
퀀 제약 (NASDAQ: QNRX)은 희귀병과 고아약에 집중하는 임상 단계 전문 제약 회사로, 2024년 11월 7일 목요일 시장 개장 전에 2024년 3분기 재무 결과를 발표할 것이라고 발표했습니다. 이 발표는 분기 중 회사의 성과에 대한 운영 업데이트 및 재무 주요 사항을 포함할 것입니다.
Quoin Pharmaceuticals (NASDAQ: QNRX), une société pharmaceutique spécialisée en phase clinique axée sur les maladies rares et orphelines, a annoncé qu'elle publiera ses résultats financiers du troisième trimestre 2024 avant l'ouverture du marché le jeudi 7 novembre 2024. L'annonce inclura une mise à jour opérationnelle sur les réalisations de l'entreprise au cours du trimestre et les points financiers saillants.
Quoin Pharmaceuticals (NASDAQ: QNRX), ein spezialisiertes Pharmaunternehmen in der klinischen Phase, das sich auf seltene und verwaiste Krankheiten konzentriert, gab bekannt, dass es seine Finanzergebnisse für das dritte Quartal 2024 vor Markteröffnung am Donnerstag, den 7. November 2024, veröffentlichen wird. Die Ankündigung wird ein operatives Update über die Erfolge des Unternehmens im Quartal sowie finanzielle Höhepunkte enthalten.
- None.
- None.
ASHBURN, Va., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage specialty pharmaceutical company focused on rare and orphan diseases, announced today that the Company plans to release its third quarter 2024 financial results before the market opens on Thursday, November 7, 2024.
The announcement will provide an operational update regarding the Company’s achievements during the quarter and will detail financial highlights.
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.
Cautionary Note Regarding Forward Looking Statements
The Company cautions that statements in this press release that are not a description of historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words referencing future events or circumstances such as “expect,” “intend,” “plan,” “anticipate,” “believe,” and “will,” among others. All statements that reflect the Company’s expectations, assumptions, projections, beliefs, or opinions about the future, other than statements of historical fact, are forward-looking statements. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon the Company’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements. For additional information concerning factors that could cause actual results to differ materially from the information contained in this press release, please see the Company’s Annual Report on Form 10-K for the year ended December 31, 2023 that the Company filed with the SEC and the Company’s subsequent filings with the SEC on Forms 10-Q and 8-K. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.
For further information, contact:
Investor Relations
PCG Advisory
Jeff Ramson
jramson@pcgadvisory.com
(646) 863-6341
FAQ
When will Quoin Pharmaceuticals (QNRX) release Q3 2024 earnings?
What will be included in Quoin Pharmaceuticals (QNRX) Q3 2024 earnings release?
What is Quoin Pharmaceuticals (QNRX) main business focus?
